Article

Applied Clinical Trials

Applied Clinical Trials

Applied Clinical Trials-11-01-2001
Volume8
Issue 11

Enterprise Services Automation Software

Web-based ESA applications provide an infrastructure that can improve the success rate of outsourcing relationships.

External Link - article-3572.pdf

Articles in this issue
Enterprise Services Automation Software
Stephen Senn
Bridging the Gap Between IT and Clinical Operations
Wireless Data: Challenges in the New New Economy
Educating Investigators to Understand When to Break the Blind
Bioterrorism and Research Policy

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Subscribe Now!
Related Videos
The Reality of Operational Flexibility for Trial Sites
The Reality of Operational Flexibility for Trial Sites
Apreo Health Launches Pivotal BREATHE-3 Trial for Severe Emphysema
Apreo Health Launches Pivotal BREATHE-3 Trial for Severe Emphysema
Future-Proofing Trial Protocols to Avoid CRLs
Future-Proofing Trial Protocols to Avoid CRLs
Related Content
How In-Home and Community Strategies Boost Recruitment and Diversity
August 20th 2025

How In-Home and Community Strategies Boost Recruitment and Diversity

Andy Studna, Senior Editor
ACT Brief Episode 4: New Data on Trial Delays, Hybrid Payment Models, and Managing Complexity
August 20th 2025

ACT Brief Episode 4: New Data on Trial Delays, Hybrid Payment Models, and Managing Complexity

Andy Studna, Senior Editor
Phase II Trial Demonstrates Encouraging Anti-Tumor Activity in Non-Small Cell Lung Cancer with sac-TMT
August 20th 2025

Phase II Trial Demonstrates Encouraging Anti-Tumor Activity in Non-Small Cell Lung Cancer with sac-TMT

Don Tracy, Associate Editor
ACT Brief Episode 3: Breaking Down Data Silos to Accelerate Clinical Trials
August 20th 2025

ACT Brief Episode 3: Breaking Down Data Silos to Accelerate Clinical Trials

Andy Studna, Senior Editor
Phase II Trial Data Lead to FDA Breakthrough Therapy Designation for Ifinatamab Deruxtecan in Extensive-Stage Small Cell Lung Cancer
August 20th 2025

Phase II Trial Data Lead to FDA Breakthrough Therapy Designation for Ifinatamab Deruxtecan in Extensive-Stage Small Cell Lung Cancer

Don Tracy, Associate Editor
© iDoPixBox - © iDoPixBox - stock.adobe.com
August 20th 2025

FDA Grants Breakthrough Therapy Designation to Izalontamab Brengitecan for EGFR-Mutated NSCLC

Andy Studna, Senior Editor
© 2025 MJH Life Sciences

All rights reserved.